Toni K. Choueiri, MD, and Laurence Albiges, MD, PhD, on Urothelial, RCC, and Other GU Malignancies: Two Key Trials

Posted: Tuesday, September 12, 2017

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, and Laurence Albiges, MD, PhD, of Gustave Roussy, discuss study findings on cabozantinib plus nivolumab and cabozantinib-nivolumab plus ipilimumab in patients with metastatic urothelial carcinoma and other genitourinary tumors; and lenvatinib plus pembrolizumab in patients with renal cell carcinoma.